Increased Atherothrombotic Burden in Patients with Diabetes Mellitus and Acute Coronary Syndrome: a Review of Antiplatelet Therapy

Overview

Journal Cardiol Res Pract

Publisher Wiley

Specialty Cardiology & Vascular Diseases

Date 2012 Feb 21

PMID 22347666

Citations 12

Authors

Karthik Balasubramaniam

Girish N Viswanathan

Sally M Marshall

Azfar G Zaman

Affiliations

Soon will be listed here.

Abstract

Patients with diabetes mellitus presenting with acute coronary syndrome have a higher risk of cardiovascular complications and recurrent ischemic events when compared to nondiabetic counterparts. Different mechanisms including endothelial dysfunction, platelet hyperactivity, and abnormalities in coagulation and fibrinolysis have been implicated for this increased atherothrombotic risk. Platelets play an important role in atherogenesis and its thrombotic complications in diabetic patients with acute coronary syndrome. Hence, potent platelet inhibition is of paramount importance in order to optimise outcomes of diabetic patients with acute coronary syndrome. The aim of this paper is to provide an overview of the increased thrombotic burden in diabetes and acute coronary syndrome, the underlying pathophysiology focussing on endothelial and platelet abnormalities, currently available antiplatelet therapies, their benefits and limitations in diabetic patients, and to describe potential future therapeutic strategies to overcome these limitations.

Citing Articles

Uric Acid to Albumin Ratio as a Predictive Marker for Intracoronary Thrombus Severity in ST-Segment Elevation Myocardial Infarction (STEMI) Patients Undergoing Primary Percutaneous Coronary Intervention (PCI).

Duman H, Ipek E, Durak H, Sahin M, Ergul E, Yilmaz A Med Sci Monit. 2024; 30:e945832.

PMID: 39425464 PMC: 11497856. DOI: 10.12659/MSM.945832.

Effect of an Integrated Naturopathy and Yoga Program on Long-Term Glycemic Control in Type 2 Diabetes Mellitus Patients: A Prospective Cohort Study.

Bairy S, Rao M, Edla S, Manthena S, Tatavarti N Int J Yoga. 2020; 13(1):42-49.

PMID: 32030020 PMC: 6937879. DOI: 10.4103/ijoy.IJOY_32_19.

Salvianolic acid a inhibits platelet activation and aggregation in patients with type 2 diabetes mellitus.

Zhou A, Xiang Y, Liu E, Cai C, Wu Y, Yang L BMC Cardiovasc Disord. 2020; 20(1):15.

PMID: 31931718 PMC: 6956554. DOI: 10.1186/s12872-019-01316-z.

Dietary program and physical activity impact on biochemical markers in patients with type 2 diabetes: A systematic review.

Barreira E, Novo A, Vaz J, Pereira A Aten Primaria. 2017; 50(10):590-610.

PMID: 29061310 PMC: 6836882. DOI: 10.1016/j.aprim.2017.06.012.

Tissue factor levels in type 2 diabetes mellitus.

Soma P, Swanepoel A, Bester J, Pretorius E Inflamm Res. 2017; 66(5):365-368.

PMID: 28246677 DOI: 10.1007/s00011-017-1030-x.

References

Kon Koh K, Quon M, Han S, Ahn J, Lee Y, Shin E . Combined therapy with ramipril and simvastatin has beneficial additive effects on tissue factor activity and prothrombin fragment 1+2 in patients with type 2 diabetes. Atherosclerosis. 2006; 194(1):230-7. DOI: 10.1016/j.atherosclerosis.2006.07.031. View

Gerrits A, Koekman C, Yildirim C, Nieuwland R, Akkerman J . Insulin inhibits tissue factor expression in monocytes. J Thromb Haemost. 2008; 7(1):198-205. DOI: 10.1111/j.1538-7836.2008.03206.x. View

Bernard S, Loffroy R, Serusclat A, Boussel L, Bonnefoy E, Thevenon C . Increased levels of endothelial microparticles CD144 (VE-Cadherin) positives in type 2 diabetic patients with coronary noncalcified plaques evaluated by multidetector computed tomography (MDCT). Atherosclerosis. 2008; 203(2):429-35. DOI: 10.1016/j.atherosclerosis.2008.07.039. View

Schafer A . Antiplatelet therapy. Am J Med. 1996; 101(2):199-209. DOI: 10.1016/s0002-9343(96)80077-5. View

Munzel T, Keaney Jr J . Are ACE inhibitors a "magic bullet" against oxidative stress?. Circulation. 2001; 104(13):1571-4. DOI: 10.1161/hc3801.095585. View

Angiolillo D, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass T . Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007; 49(14):1505-16. DOI: 10.1016/j.jacc.2006.11.044. View

Laakso M . Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes. 1999; 48(5):937-42. DOI: 10.2337/diabetes.48.5.937. View

Wilson P, DAgostino R, Levy D, Belanger A, Silbershatz H, Kannel W . Prediction of coronary heart disease using risk factor categories. Circulation. 1998; 97(18):1837-47. DOI: 10.1161/01.cir.97.18.1837. View

Henriksen E . Improvement of insulin sensitivity by antagonism of the renin-angiotensin system. Am J Physiol Regul Integr Comp Physiol. 2007; 293(3):R974-80. DOI: 10.1152/ajpregu.00147.2007. View

10.

Yusuf S, Zhao F, Mehta S, Chrolavicius S, Tognoni G, Fox K . Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345(7):494-502. DOI: 10.1056/NEJMoa010746. View

11.

. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25):3143-421. View

12.

Lefkovits J, Plow E, Topol E . Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med. 1995; 332(23):1553-9. DOI: 10.1056/NEJM199506083322306. View

13.

Angiolillo D, Bernardo E, Capodanno D, Vivas D, Sabate M, Ferreiro J . Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. J Am Coll Cardiol. 2010; 55(11):1139-46. DOI: 10.1016/j.jacc.2009.10.043. View

14.

Xia P, Inoguchi T, Kern T, ENGERMAN R, Oates P, King G . Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes. 1994; 43(9):1122-9. DOI: 10.2337/diab.43.9.1122. View

15.

Lonn E, Yusuf S, Hoogwerf B, Pogue J, Yi Q, Zinman B . Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. Diabetes Care. 2002; 25(11):1919-27. DOI: 10.2337/diacare.25.11.1919. View

16.

Gao L, Mann G . Vascular NAD(P)H oxidase activation in diabetes: a double-edged sword in redox signalling. Cardiovasc Res. 2009; 82(1):9-20. DOI: 10.1093/cvr/cvp031. View

17.

Brezinka V, Padmos I . Coronary heart disease risk factors in women. Eur Heart J. 1994; 15(11):1571-84. DOI: 10.1093/oxfordjournals.eurheartj.a060432. View

18.

Harrington R, Stone G, McNulty S, White H, Lincoff A, Gibson C . Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med. 2009; 361(24):2318-29. DOI: 10.1056/NEJMoa0908628. View

19.

Hu H, Li N, Yngen M, Ostenson C, Wallen N, Hjemdahl P . Enhanced leukocyte-platelet cross-talk in Type 1 diabetes mellitus: relationship to microangiopathy. J Thromb Haemost. 2004; 2(1):58-64. DOI: 10.1111/j.1538-7836.2003.00525.x. View

20.

Vandendries E, Furie B, Furie B . Role of P-selectin and PSGL-1 in coagulation and thrombosis. Thromb Haemost. 2004; 92(3):459-66. DOI: 10.1160/TH04-05-0306. View